Merck


All three pillars are getting squeezed

24/03/20 -"Against the background of the to-be-expected recession, management's lifted dividend proposal of €1.30 per share looks far too optimistic, but, one has to bear in mind, the company is family-owned ..."

Pages
75
Language
English
Published on
24/03/20
You may also be interested by these reports :
04/11/25
The Q3 operating profitability exceeded expectations, though sales fell short of consensus. The management reaffirmed its full-year guidance. While ...

03/11/25
BioNTech reported mixed Q3 results. Sales significantly exceeded market expectations, but the operating loss was higher than anticipated. The 2025 ...

31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...

30/10/25
While Q3 sales fell marginally short of the street’s expectations, a healthily growing high-margin Biosimilars segment led to the 2025 profitability ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO